[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai UniXell Biotechnology Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100649365","phase-1-phase-iii-clinical-trial-of-ux-da003-injection-for-the-treatment-of-patients-with-parkinsons-disease-100649365",false,"NCT07733349","Phase I\u002FII Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease","Phase I\u002FII Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of UX-DA003 Injection in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Aged between 30 and 75 years, regardless of gender\n* Diagnosed with Parkinson's disease conforming to relevant clinical diagnostic standards with a medical history of 5-20 years\n* Having received standard anti-PD treatment and been given optimal anti-PD treatment under the guidance of the investigator, but the efficacy has significantly declined\n* Good response to levodopa medications, the levodopa challenge test (LCT) shows that the maximum improvement rate of the UPDRS-III score exceeds 30%\n* The modified H\\&Y staging (Off period) of ≥2.5 and ≤4, with total daily \"off\" time \\>2 hours\n* Stable dose of anti-Parkinson' disease drugs for at least 4 weeks prior to screening\n* Good physical condition or stable concomitant diseases\n\nExclusion Criteria:\n\n* The subjects with atypical Parkinson's syndrome or secondary Parkinson's syndrome\n* Severe systemic diseases or functional impairments\n* Evidence of active infection or chronic infection, which may pose a risk to the subject\n* Severe concomitant central nervous system diseases or severe cognitive and psychiatric disorders\n* Subjects with a history of brain injuries, cerebral vascular malformations, hydrocephalus, brain tumors, or other brain damages as shown by previous Head CT\u002FMRI scans, or subjects with abnormal brain imaging in the striatum or other brain regions that significantly increase surgical risks\n* Subjects who have participated in clinical trials for stem cell therapy or gene therapy for Parkinson's disease, or have participated in other interventional clinical trials within the last 3 months\n* Subjects with a history of severe allergies or hypersensitivity reactions, known hypersensitivity to the investigational drug or its ancillary materials, or intolerance to them\n* Pregnant or breastfeeding women","ALL","30 Years","75 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.",[28],"Parkinson's Disease",[30,28],"allogeneic iPSC derived mDAPs","NOT_YET_RECRUITING","2026-07-24",{"date":34,"type":35},"2026-07-29","ACTUAL",{"date":37,"type":21},"2026-08-03",{"date":39,"type":21},"2032-08-31",{"name":41,"class":42},"Shanghai UniXell Biotechnology Co., Ltd","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100636986","phase-1-a-phase-i-clinical-trial-of-ux-gip001-in-the-treatment-of-drug-resistant-unilateral-mesial-temporal-lobe-epilepsy-100636986","NCT07572812","A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of UX-GIP001 (Human GABAergic Interneuron Progenitor Cells Injection) in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy","Inclusion Criteria:\n\n* Age 18-75 years (inclusive), male or female;\n* Diagnosis of focal epilepsy according to the International League Against Epilepsy (ILAE) 2025 epilepsy classification, with disease duration ≥2 years;\n* Clinical presentation consistent with unilateral mesial temporal lobe epilepsy (MTLE);\n* Meeting the diagnostic criteria for drug-resistant epilepsy;\n* Average focal seizure frequency ≥4 per 28 days within the 3 months prior to screening;\n* On a stable dose of anti-seizure medications for ≥1 month prior to enrollment;\n* Patient has adequate organ function as follows: absolute neutrophil count ≥2.0×10⁹\u002FL; white blood cell count ≥4.0×10⁹\u002FL; platelet count ≥100×10⁹\u002FL; AST and ALT ≤2.5× upper limit of normal (ULN); total bilirubin ≤1.5× ULN; serum creatinine ≤1.5× ULN; estimated glomerular filtration rate (eGFR) ≥60 mL\u002Fmin\u002F1.73 m² (calculated using the CKD-EPI formula);\n* Women of childbearing potential must have a negative serum pregnancy test during the screening period. All participants and their partners agree to have no plans for pregnancy, sperm donation, or egg donation from the time of signing the informed consent form until 2 years after cell transplantation treatment, and voluntarily adopt contraceptive measures deemed effective by the investigator;\n* Patient has good compliance, with a patient diary completion rate ≥80% prior to enrollment.\n\nExclusion Criteria:\n\n* Epilepsy caused by other\u002For progressive neurological diseases , or patients - experiencing only focal aware seizures without observable manifestations.\n* History of epilepsy surgery.\n* History of status epilepticus within 12 months prior to screening.\n* Presence of long-term implants in the skull or intracranial space.\n* Severe systemic disease or dysfunction.\n* Primary or secondary immunodeficiency.\n* History of clear suicidal intent, plan, or behavior within one year prior to screening.\n* Severe psychiatric disorders.\n* History of malignancy within the past 5 years, except for cervical carcinoma in situ, basal cell or squamous cell skin cancer cured for \\>5 years.\n* Pregnant or breastfeeding women.","18 Years",{"count":20,"type":21},[24],"This is a phase I study (Protocol: UX-GIP001-102) investigating UX-GIP001 Injection, a novel cell therapy product consisting of human GABAergic interneuron progenitor cells (GIP), for treating adult patients with drug-resistant unilateral medial temporal lobe epilepsy (MTLE). The primary objective is to assess the safety, tolerability, and preliminary efficacy of UX-GIP001. This is an open-label, single-arm study. All enrolled participants will receive the active investigational cell therapy. Seizure frequency and safety parameters will be evaluated by comparing post-transplant outcomes to pre-transplant baselines.",[56],"Epilepsy",[56,58,59],"MTLE","Cell therapy",{"date":61,"type":35},"2026-07-27",{"date":63,"type":21},"2026-08-20",{"date":65,"type":21},"2029-07-01",{"name":41,"class":42},3,""]